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Available online 5 March 2008Polo-like kinases (Plks) contain a conserved Polo-box domain, shown to bind to phosphorylated Ser-pSer/
pThr-Pro motifs. The Polo-box domain of Plk-1 mediates substrate interaction and plays an important role in
subcellular localization. Intriguingly, the major interactions between the PBD and the optimal recognition
peptide are mediated by highly conserved residues in the PBD, suggesting there is little target speciﬁcity
conveyed by the various PBDs. However, here we show that the afﬁnity of the puriﬁed Plk1-3 PBDs to both a
physiological Cdc25C derived phospho-peptide and an optimal recognition phospho-peptide differs
signiﬁcantly among family members. To decipher the role of the PBDs and kinase domains in inferring Plk
speciﬁcity, we exchanged the PBD of Plk1 (PBD1) with the PBD of Plk2, 3, or 4 (PBD2–4). The resulting hybrid
proteins can restore bipolar spindle formation and centrosome maturation in Plk1-depleted U2OS cells to
various degrees. In these experiments PBD2 was most efﬁcient in complementing PBD-function. Using the
MPM2 antibody that recognizes a large set of mitotic phospho-proteins, we could show that PBD1 and PBD2
display some limited overlap in target recognition. Thus, PBDs convey a signiﬁcant deal of target speciﬁcity,
indicating that there is only a limited amount of functional redundancy possible within the Plk family.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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The family of polo-like kinases (Plks) inmammalian cells consists of
multiple members (Plk1, Plk2/Snk, Plk3/Fnk/Prk, and Plk4/Sak) that
regulate a variety of events throughout the cell cycle (for a review see
[1]). The foundingmember of all Plks, Polo,was identiﬁed inDrosophila
due to its essential function in the formation of bipolar spindles in
weak hypomorphs [2]. This function is conserved in human Plk1 as
injection of anti-Plk1 antibodies leads tomonopolar spindle formation
[3]. Plks also contribute to late mitotic events, like activation of the
anaphase-promoting complex/cyclosome (APC/C) and cytokinesis [1].
Plk family members have high similarity in their N-terminal
catalytic domain and C-terminal motifs named polo boxes or motifs
(PBM). The region containing two tandem Polo boxes forms a
structural unit called the Polo-box domain (PBD), which regulates
cellular function, subcellular localization and substrate interactions
[4–6]. Point-mutations in the PBD abolish subcellular localization and
affect Plk1 function in bipolar spindle formation and APC/C activation,
probably through interference with substrate interactions [6–10]. The
molecular mechanism through which PBD–protein interactions are
regulatedwas partially revealed when the Plk1 PBDwas identiﬁed in a
proteomic screen for phospho-Serine/Threonine binding motifs [5].
These data provide a molecular model in which priming phosphor-
ylation by Cdk1 directs Plk1 substrate recognition and activation in a1 30 2538479.
dema).
l rights reserved.spatial and temporal manner. Themost commonly acceptedmolecular
models argue that the kinase domain and the PBD of Plk1 inhibit each
other intra-molecularly, but these internal inhibitory actions are
relieved upon phospho-substrate binding of the PBD and/or kinase
activation [11,12]. An intriguing mechanism whereby the Connecting
Loop (CL) between the two PBMs of the PBD is ordered upon binding
of a phosphorylated substrate (but is not ordered when bound to the
same substrate when not primed) and triggers Plk1 activity, has also
recently been put forward [13].
Similar to Plk1, Plk2–4 contain the highly conserved kinase domain
and PBD. Like Plk1, Plk2–4 have all been shown to localize to
centrosomes [14–16] and at least for mouse Plk2 and 4, this
centrosome localization is also dependent on the PBD [16,17]. The
PBDs from Plk2 and 3 can also bind phospho-Ser/Thr-containing
motifs [11] and the C-terminus of Plk2 can negatively regulate its
kinase activity [18]. Plk4 differs from Plk1-3 in that it has only a single
polo box, that forms intermolecular dimers [19]. These dimers broadly
resemble the structure formed by the two polo boxes of Plk1, but the
residuesmost intimately involved in phospho-peptide binding by Plk1
are not conserved in Plk4 [11,20]. Therefore, it remains to be
determined whether the PBD of Plk4 can function as a phospho-
protein binding motif.
Despite themany similarities between Plk1–4, multiple differences
exist between the roles that they play in the cell cycle. Plk2 has been
implicated in centriole duplication and prevents mitotic catastrophe
induced by spindle poisons [14,18]. However, Plk2 does not appear to
be absolutely essential during the cell cycle, since Plk2−/− mice are
1016 B.C.M. van de Weerdt et al. / Biochimica et Biophysica Acta 1783 (2008) 1015–1022viable with only mildly retarded growth [21]. Plk3, like Plk1, can
rescue a Cdc5-mutation in budding yeast, suggesting functional
overlap [22,23]. However, Plk3 can phosphorylate the Cdk1-activating
phosphatase Cdc25C, but this leads to inhibition of Cdk1 instead of the
activation of Cdc25C observed after phosphorylation by Plk1 [24].
Whereas Plk1 activity is inhibited after DNA damage [25], Plk3 is
activated [26]. Plk4 is a gene essential for cell viability [27]. Plk4−/−
embryos arrest at E7.5 with amarked increase inmitotic and apoptotic
cells [16].
2. Materials and methods
2.1. Cells and plasmids
U2OS-derived human osteosarcoma UTA6 cells were grown in Dulbecco's modiﬁed
Eagle's medium with 6% fetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin.
Histone H2B–GFP [28], the siRNA vector pS [29], pS-Plk1 and Plk1-sil [30], all have been
described. YFP-α-tubulin was kindly provided by J. Kuiper (Hubrecht Laboratory,
Utrecht, The Netherlands). pEGFP-C1-Plk2 (Snk) and Plk3 (Prk) were a kind gift of
G. Vader (Utrecht, The Netherlands). Plk4-FLAG was a gift from H. Mano (Jichi Medical
School, Tochigi, Japan). VSV-tagged PBD1–4 were constructed from the above described
plasmids by creating XhoI and XbaI sites ﬂanking the PBDs by PCR and cloning them
into a derivative of pCR3 (MT044), in-frame with an N-terminal VSV-tag. For cloning
Kin1, EcoRI and XhoI sites were used. Subsequently, XhoI–XbaI-cut PBD1–4were cloned
into XhoI–XbaI-cut MT044-Kin1 to generate Kin-PBD hybrids. Plk1-FL was cloned into
MT044 after creating EcoRI and XbaI sites ﬂanking Plk1 by PCR. All clones were veriﬁed
by automated sequencing. Alignment of Plk1-4 was performed using Vector NTI
software (InforMax Inc., Bethesda, MD).
2.2. Transfections
Transient transfections were performed using the standard calcium phosphate
transfection protocol. For immunoblotting, 10 µg of the empty siRNA vector pS or pS-
Plk1 was co-transfected with 1 µg of a vector containing puromycin-resistance
combined with the indicated mutants. Different amounts of reconstitution plasmids
were used to equalize expression levels. Puromycin (2 μg/ml) and thymidine (2.5 mM;
both from Sigma, St. Louis, MO) were added about 8 h after washing away the calcium
phosphate precipitate. After 24 h of puromycin selection, cells were washed and
puromycin-free medium was added, releasing the cells from thymidine block at the
same time. Another 17 h later, cells were harvested and lysed for immunoblotting. For
time-lapse microscopy, immunoﬂuorescence staining or kinase assays, no puromycin
selection was used, but cells were only arrested in thymine and released. Where
indicated cells were treated with BI2536 (a kind gift of Boehringer Ingelheim) at a ﬁnal
concentration of 100 ng/ml.
2.3. Antibodies
Mouse anti-VSV, rabbit anti-γ-tubulin and mouse anti-α-tubulin antibodies were
from Sigma. Mouse anti-Cdh1 was from Neomarkers, and rabbit anti-FoxM1/Mpp2 was
from Santa Cruz (C-20). Rabbit anti-Aurora A was from Cell Signaling Technology
(Beverly, MA). Peroxidase-conjugated rabbit anti-mouse antiserum for immunoblotting
was from DAKO (Glostrup, Denmark). Alexa antibodies anti-mouse-568, -rabbit-468,
-rabbit-568 and -rabbit-647 for immunoﬂuorescence were from Molecular Probes
(Eugene, OR).
2.4. Immune ﬂuorescence and time-lapse microscopy
Immune ﬂuorescence was performed as described [30]. For determining spindle
bipolarity and Aurora A localization, 3 and 5 independent experiments were averaged,
respectively, with at least 50 transfected cells counted per condition. Time-lapse
microscopy was performed as described [31]. Quantiﬁcation of γ-tubulin intensity on
mitotic centrosomes was performed as described previously [30].
2.5. Kinase assays
After 15 h release from thymidine arrest, cells were lysed and subjected to VSV-
immuneprecipitation kinase assays using α-casein as substrate [31].
2.6. Production of recombinant PBDs
For pull-down experiments all four PBDs were cloned into pGEX-6P-1 harboring a
GST tag. Vectors were transformed to Rosetta-2 cells (Novagen), and protein production
was induced with IPTG at 30 °C at an optical density of 0.6 for 3 h. Cell pellets were
obtained by centrifugation at 4000 rpm and lysed by sonication in 20mMHepes pH 7.5,
200 mMNaCl, 5 mM β-mercaptoethanol, (buffer A) plus a tablet of Complete EDTA-free
(Roche) at 4 °C. After clearing the supernatant by centrifugation, GST–PBD fusions were
bound to a GST-trap column (GE Healthcare) and eluted with the buffer A containing
30 mM glutathione. Fractions were analyzed by SDS-PAGE and pure fractions werepooled. Yields were about 25mg/ml for PBD1, 40mg/ml for PBD2,1mg/ml for PBD3 and
25 mg/ml PBD4. GST protein alone, to be used as control, was puriﬁed in a similar
manner. All proteins were more than 95% pure as judged by SDS-PAGE. For surface
plasmon resonance experiments PBD 1, 2 and 3 constructs optimized for solubility were
cloned into a pET28 vector harboring a precision-protease cleavable His-tag fused at the
N-terminus (MAHHHHHHSAALEVLFQGPG). Vectors were then transformed into BL21
(DE3) cells (Novagen). Protein was produced by inducing for 12 h with 0.5 mM IPTG at
15 °C once an optical density of 0.6 was reached. Cells were harvested by centrifugation
at 4000 rpm and lysed by sonication in 20 mMHepes pH 7.5, 200 mMNaCl, 0.5 mM Tris
(2-Carboxyethyl)phosphine/HCl, (buffer A) plus a tablet of Complete EDTA-free (Roche)
at 4 °C. After clearing the supernatant by centrifugation, His-PBD fusions were bound to
a Nickel-NTA column (GE Healthcare) and eluted with buffer A containing 100 mM
Imidazole. At this stage the His-tag of PBD1 and PBD3 (PBD2 was unstable if the tag was
removed) was removed by a 4 °C overnight cleavage with a His-tagged precision-
protease, after cleavage the product was passed back over a Ni-NTA column and the
ﬂow-through collected. The eluted protein was then passed over a S200 16/60 gel
ﬁltration column (GE Healthcare). Fractions were analyzed by SDS-PAGE and pure
fractions were pooled.
2.7. PBD pull-downs and analysis
Cells were synchronized in G1/S by thymidine (2.5 mM for 16 h) and subsequently
released for 7 h. Cells were then incubated with doxorubicin (0.5 μM) or taxol (1 μM) for
24 h in order to obtain respectively G2- and M-phase cells. G2-phase cells were
harvested by trypsinization, mitotic cells were collected bymitotic shake-off. Cells were
lysed in 2 ml lysis buffer (20 mM Tris–HCl pH 8.0, 250 mM NaCl, 1 mM EDTA, 0.5% NP-
40, 5 mM β-mercaptoethanol, 20 mM NaF, 25 mM β-glycerophophate, 1 tablet of
Complete EDTA-free per 50 ml) on ice for 30 min. The lysate was cleared by
centrifugation and incubated with GST–PBD (120 μg) on 0.5 ml Handee Spin Columns
(Pierce). To this end, 200 μl of the lysate was added together with 300 μl of washing
buffer (20 mM Tris–HCl pH 8.0, 250 mM NaCl, 1 mM EDTA, 0.5% NP-40, 5 mM β-
mercaptoethanol) and columns were left on a rotating plate for 1 h at 4 °C. Beads and
the bound protein were washed extensively with washing buffer, after which bound
protein was eluted with boiling 2× sample buffer. 20 μl of each sample was analyzed by
Western blotting with the appropriate antibodies.
2.8. Surface plasmon resonance experiments
Surface plasmon resonance (SPR) spectroscopy was preformed at 25 °C on a Biacore
T100. About 60 RU of MALPMQ-S-pT-P-LNGAKK (optimal) and LLC-S-pT-P-NGLKK
(Cdc25C) peptides were immobilized on a CM5 Chip (Biacore) at pH 4.5 using amino
coupling of the terminal Lysine residues. Concentrations series of different PBDs in
20 mM Hepes pH 7.5, 200 mM NaCl were injected across the chip at 30 µl/min. Binding
curves were recorded for each protein, using the empty ﬂow cell as reference. The
Biacore T100 evaluation software was used for the initial data analysis. The Prism 4.03
(GraphPad Software) software was used for equilibrium constant calculation and
ﬁgures creations.
3. Results
3.1. PBDs have signiﬁcantly different afﬁnities for ‘optimal’ and
physiological phospho-peptides
An optimal phospho-peptide substrate that binds the PBD from
Plk1 (PBD1) has been identiﬁed [5] and further characterized [11] by
Yaffe and co-workers. In these experiments human Plk1, 2 and 3 PBDs
showed unequivocal selection for a Ser-pThr-Pro motif, with no
reported differences. Based on the crystal structure of the complex of
the PBD of Plk1 with the optimal phospho-peptide [11,20] (PMQS[pT]
PL, Suppl. Fig. 1A) and the more recent structure of PBD1 with a
physiological Cdc25C peptide [13] (LLC-S-[pT]-P-N, Suppl. Fig. 1B) one
would indeed expect PBD1, 2 and 3 to have similar afﬁnities for
primed target peptides. However, we observed signiﬁcant differences
in the binding of the optimal phospho-peptide (MAGPMQ-S-pT-P-
LNGAKK) and of the physiological Cdc25C phospho-peptide (LLC-S-
[pT]-P-N) to PBDs1–3. Puriﬁed PBDs 1–3 were used as analytes to test
their binding to immobilized peptides in a surface plasmon resonance
(SPR) experiment (Table 1, Suppl. Fig. 2). The optimal partner for the
peptide is PBD1, with an apparent kD of about 31 nM for the optimal
and 82 nM for the physiological peptide. PBD2 binds one hundred
times weaker to the optimal phospho-peptide (kD of 4900 nM) and
with an afﬁnity less than 5 μM to the Cdc25C phospho-peptide. The
afﬁnity of PBD3 to either phospho-peptides is signiﬁcantly worse
than 5 μM. According to the crystal structures available to date
Fig.1. Expression of PBD-swapmutants. (A) Schematic representation of the boundaries
of the kinase and polo box domain in all Plks denoted kinase and PBD, respectively.
(B) Schematic representation of the PBD substitution mutants. (C) U2OS cells were
transiently transfected with the indicated plasmids and harvested after puromycin
selection for transfected cells and 17 h thymidine release. Expression was examined
with a VSV antibody on immunoblot (upper panel) with α-tubulin as a loading control
(middle panel). Using a similar experimental setup but without puromycin selection, in
vitro kinase assays were performed after VSV-immuneprecipitation using α-casein as a
substrate (lower panel).
Table 1
Afﬁnities of puriﬁed PBD1–3 to an optimal and a Cdc25C derived phospho-peptide
PBD1 PBD2 PBD3
Optimal 31±2 nM 4900±300 nM NN5000 nM
Cdc25C 82±2 nM NN5000 nM NN5000 nM
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explained on a structural basis. We also note that all PBDs are active,
since they all bindwell (afﬁnity about 500 nM) to non-phosphorylated
Cdc25C peptides (manuscript in preparation).
3.2. Construction and expression of PBD-swaps of Plk1
To study the functional speciﬁcity endowed by the PBD, we
replaced PBD1 in Plk1 by PBD2, 3 or 4. The PBD domain boundaries
were designed based on a sequence alignment and using the polo
boxes and the polo-cap sequence (Pc) that was shown to be essential
for proper folding [11] (Fig. 1A). The N-terminal kinase domain of Plk1
(Kin1), which contains part of the linker region, was fused to the PBDs
from Plk1–4 (Fig. 1B). The PBD-swap mutants that were constructed
as such were denoted as Kin1–PBD1, Kin1–PBD2, Kin1–PBD3 and
Kin1–PBD4 (Fig. 1B). In addition to the swap mutants, expression
constructs were made harboring the PBD1–4 domains alone. Also a
mutant encoding only the Plk1 kinase domain, Kin1, was constructed
for the appropriate control experiments. All constructs harbor an N-
terminal VSV-tag to enable localization experiments.
To study the function of the PBD-swap mutants without possible
interference of endogenous Plk1, we depleted Plk1 by vector-driven
siRNA [30]. The siRNA is directed against the PBD region of Plk1, where
all three swap mutants have between six and seven mismatches; thus
all three domain swap mutants are not targeted by the siRNA vector
used to target Plk1. The full length Plk1(Plk1-ﬂ) and the Kin1–PBD1
vectors were constructedwith two silent point mutations in the target
sequence recognized by the RNAi-vector, rendering them resistant to
knock-down [30,31]. Human osteosarcoma U2OS cells depleted of
endogenous Plk1 were co-transfected with expression vectors for the
various PBDs or the PBD-swapmutants in combinationwith a plasmid
carrying a selectable marker gene to obtain a pure population of
transfected cells. All mutants were expressed, with the exception of
the PBD4 alone and the Kin1–PBD4 fusion (Fig. 1C). Since Plk4
contains multiple PEST sequences, we shortened the 5′ end of PBD4
(Fig. 1B, PBD4ΔPEST), fused it to Kin1 and examined expression.
Expression of PBD4ΔPEST alone was still not detected, but the Kin1–
PBD4ΔPEST fusion was expressed and was used in all further
experiments (Fig. 1C). Importantly, Kin1–PBD1, 2 and 3 mutants
retained similar in vitro kinase activity towards α-casein in a VSV-IP
kinase assay, whereas the activity of the PBD–Plk4ΔPEST was
somewhat enhanced (Fig. 1C). This indicates that the described
negative regulatory activity of PBD1 on the enzymatic activity of
Plk1 [32] is also present in PDB2 and PBD3. The enhanced kinase
activity of the PBD–Plk4ΔPEST swap indicates that this negative
regulatory activity is either not retained, or depends on residues in the
PEST sequences. Importantly, these data show that any functional
differences that might exist between the various PBD-swaps is not due
to an overall loss of Plk1 kinase activity, but must result from altered
substrate recognition.
3.3. PBD-swap mutants localize to different mitotic structures
All human Plk family members are reported to localize to
centrosomes [14–16,33]; Plk1 also localizes to kinetochores [34].
The Kin1 domain alone did not show any speciﬁc localization,
whereas the PBD1 alone localizes weakly to kinetochores and
centrosomes (Suppl. Fig. 3A). This conﬁrms that PBD1 is at leastpartially responsible for subcellular targeting of Plk1, but also that the
kinase domain is important for localization [13]. We were unable to
localize PBD2–4 alone speciﬁcally in mitotic cells (data not shown),
even though previous reports have shown centrosome localization of
Plk2–4 [14–16,33]. We ﬁnd that both the Kin1–PBD2 and Kin1–
PBD4ΔPEST swap mutants, but not the Kin1–PBD3 mutants, localize
at centrosomes in mitosis, indicating that their recruitment during
mitosis is dependent on the presence of the Plk1 kinase domain. This
observation, together with the fact that earlier localization studies
were not done in a Plk1-deﬁcient background as we used here,
suggests that recruitment of Plk2–4 to centrosomes might be
dependent on Plk1 kinase activity. To further corroborate this notion,
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swaps in the presence or absence of a well-characterized Plk-inhibitor
BI2536 [35,36]. We ﬁnd that the recruitment of all swaps to the
centrosomes is unperturbed by BI2536 in interphase (Suppl. Fig. 3B),
indicating that the interphase recruitment of PBD2–4 to centrosomes
is not dependent on Plk1 activity. However, in mitotic cells the
localization of Kin1–PBD2, Kin1–PBD3 and Kin1–PBD4ΔPEST to
centrosomes was perturbed in cells treated with BI2536 (Suppl.
Fig. 3B). This either suggests that Plk1 directly regulates the
recruitment of PBD2, 3 and 4 to centrosomes in mitotic cells, or that
recruitment of PBD2, 3 and 4 indirectly depends on Plk1-dependent
maturation of the centrosomes, which is perturbed in cells treated
with BI2536. It should be noted that the enrichment of the Kin1–PBD3
swap on the centrosomes in mitotic cells was very weak (Suppl.
Fig. 3B), consistent with the diffuse staining of Plk3 reported earlier in
mitotic A549 cells [15]. Finally it should be noted, that the Kin1–PBD2
swap also localizes to kinetochores making its overall subcellular
localization most similar to that of Kin1–PBD1 (Suppl. Fig. 3).
3.4. Functional reconstitution of Plk1-depleted cells with the PBD-swap
mutants
To study if PBD substitution mutants are able to replace endog-
enous Plk1 in regulating bipolar spindle formation, we depleted U2OS
cells of endogenous Plk1 and reconstituted these cells with the PBD-
swap mutants. Cells were synchronized in S phase by thymidine and
ﬁxed 15 h after release from the thymidine block, a time when the
mitotic index is high. Co-transfection of vector expressing α-tubulin-
YFP allowed identiﬁcation of transfected cells; staining with γ-tubulin
allowed analysis of spindle bipolarity. Bipolar spindles with mature
centrosomes were detected in nearly all mock-depleted cells (96%;
Fig. 2A, B). In contrast, in Plk1-depleted cells, only 8% of the cells dis-
played normal bipolar spindles with mature centrosomes (Fig. 2A, B).
The remaining population either had monopolar spindles (72%)
(Fig. 2A), or bipolar spindles with immature centrosomes (28%)
(Fig. 2A) as previously reported [30]. Expression of Kin1–PBD1
restored the percentage of cells with normal bipolar spindles to 76%
(Fig. 2A) and similar numbers of normal bipolar spindles were
observed when expressing the Plk1-FL control (data not shown).
Expression of the Kin1–PBD2 swap resulted in 72% of the cells having
normal bipolar spindles, in contrast to 33% and 38% normal bipolar
spindles after expression of Kin1–PBD3 and Kin1–PBD4ΔPEST
respectively (Fig. 2A). These data show that expression of all of the
PBD-swap mutants caused an increase in normal bipolar spindle
formation over Plk1-depleted cells, consistent with the observation
that mere expression of the kinase domain of Plk1 can partially restore
bipolar spindle formation [37] (Fig. 2A). However, PBD3 and PBD4 add
little in this respect to the activity of the kinase domain of Plk1. Also,
whenwe quantiﬁed centrosomematuration bymeasuring intensity of
γ-tubulin staining on the centrosomes of individual mitotic cells, we
found that centrosome maturation is much better restored by the
Kin1–PBD1 and Kin1–PBD2 swaps (Fig. 2C). Finally, PBD2 appears
equally efﬁcient in promoting bipolar spindle formation as is PBD1.
Expression of the PBD2–4 without the kinase domain failed to recon-
stitute spindle formation, and no cell cycle defects were apparent
upon expression of any single PBD (data not shown). In addition,
expression of the different Kin1–PDB swaps in cells expressing
normal levels of endogenous Plk1 did not cause any obvious
phenotype that could suggest a potent dominant negative effect of
these hybrids over normal Plk1 (data not shown). Of course it is
difﬁcult to rule out that one or more of the Kin1–PBD-swap mutants
exert a dominant negative effect only in the background of a Plk1-
depleted cell. Nonetheless, these observations rule out the possibility
that the distinct functionality of the different hybrids is due to a
dominant negative function of these PBDs over endogenous Plk1
function.3.5. Effect of PBD-swaps on Aurora A recruitment to centrosomes
Recruitment of Aurora A to centrosomes was shown to occur in a
Plk1-dependent manner [37]. In the light of the latter results and to
further explore the ability of Plk hybrids to replace Plk1 functions, we
investigated Aurora A localization. Aurora A expression was clearly
decreased on centrosomes in Plk1-depleted cells, compared to mock-
depleted cells (Fig. 2D). Three quarters (75%) of mock-depleted cells
show Aurora A localized to centrosomes and part of the spindle closest
to the centrosome (Fig. 2D), while only one quarter (27%) of Plk1-
depleted cells exhibit Aurora A on centrosomes and part of the spindle
(for examples of different Aurora A localization see Fig. 2E). The
remaining Plk1-depleted cells show increased spindle localization
with no/weak centrosome staining (37%) or no/weak detectable
Aurora A anywhere in the cell (36%; Fig. 2D). Since depletion of Plk1
does not lead to overall reduction in the expression level of Aurora A
(data not shown), the observed effect is truly due to changes in
localization. Thus, centrosome localization of Aurora A depends on the
presence of Plk1. Kin1–PBD1 and Kin1–PBD2 were both able to
completely restore Aurora A levels on centrosomes (Fig. 2D), whereas
Kin1–PBD3 or Kin1–PBD4ΔPEST restored Aurora A recruitment only
partially, similar to the ability of these mutants to rescue centrosome
maturation.
3.6. Mitotic progression in cells expressing PBD-swaps
Monopolar spindle formation observed in U2OS cells depleted of
Plk1 leads to a prolonged prometaphase arrest [30,38]. Since
expression of Kin1–PBD2 partially restores bipolar spindle formation,
we tested whether Kin1–PBD2 could alleviate the prometaphase
arrest seen in Plk1-depleted cells. However, while expression of the
Kin1–PBD1 reverted the mitotic arrest induced by depletion of Plk1
(Fig. 3A), expression of the Kin1–PDB2, Kin1–PBD3 or Kin1–
PBD4ΔPEST did not shorten the mean duration of mitosis in cells
depleted of endogenous Plk1 (Fig. 3A and data not shown). This
indicates that although bipolar spindle formation is partially restored
in cells reconstitutedwith the Kin1–PBD2 swap, mitotic progression is
still perturbed. Indeed, expression of Kin1–PBD2 or Kin1–PBD4ΔPEST
failed to restore normal chromosome alignment, which was restored
upon expression of Kin1–PBD1 (Fig. 3B). Nonetheless, in Kin1–PBD2
cells, partial restoration of chromosome alignment was evident, as
36% of cells rescued with Kin1–PBD2 were able to fully align their
chromosomes, but this took more than 45 min. (Fig. 3B and Suppl.
Fig. 4). In addition, another 55% of the cells did align all chromosomes,
but this alignment appeared unstable with chromosomes detaching
from the metaphase plate for short or long periods (Fig. 3B and Suppl.
Fig. 4). Thus, chromosome alignment was rescued better with Kin1–
PBD2 than Kin1–PBD4ΔPEST, but overall full alignmentwas delayed or
the alignment was unstable. Reconstitution with Kin1–PBD3 resulted
in mitotic progression defects that were similar to what we observed
with Kin1–PBD4ΔPEST (data not shown).
3.7. PBDs have different afﬁnities for Plk partners
To extend our in vivo observations on the ability of PBDs2–4 to
complement PBD1 function, we performed a series of pull-down
experiments using GST-tagged PBD's and lysates prepared from U2OS
cells arrested in either the M or G2 phase. A few well-characterized
Plk1 interactors, namely Cdc25C, FOXM1, Claspin and Cdh1 could be
pulled-down from a mitotic lysate using GST–PBD1 as bait (Fig. 4A).
FoxM1 and Claspin from interphase extracts did also display a weak
afﬁnity for GST–PBD1 (Fig. 4A). None of the other GST–PBD fusions
displayed signiﬁcant afﬁnity for any of these proteins, with the
possible exception of Cdh1, which was weakly recognized by GST–
PBD2 and 3 in mitotic extracts (Fig. 4A). These experiments indicate
that rescue of spindle bipolarity by the Kin1–PBD2 swap cannot be
Fig. 2. Spindle formation in Plk1-depleted cells reconstituted with PBD-swap mutants. (A) Spindle polarity was scored in at least 50 mitotic α-tubulin-YFP-containing cells transfected with the indicated plasmids. We determined whether
spindles were bipolar (black bars), monopolar (grey bars) or multipolar (white bars). The average of 5 independent experiments is shown plus standard deviation. (B) Examples of spindle morphology in cells expressing the indicated plasmids.
Merges of z-stacks are shown. (C) Relative amounts of γ-tubulin intensity in segmented areas around the centrosomes of pS- or pS-Plk1-transfected U2OS cells reconstituted with the indicated Kin1-PBD-swap mutants. Average and S.E. of 10
transfected cells are shown. (D) AuroraA localizationwas scored inmitoticα-tubulin-YFP containing cells transfectedwith the indicatedmutants. Centrosome staining (black bars), spindle staining (grey bars) or veryweak/no stainingwas scored
in at least 50 cells per coverslip in 3 independent experiments. Standard deviation is shown. (E) Examples of cells expressing Aurora A on centrosomes or the spindle, or showing no/low Aurora A expression. Merges of z-stacks are shown.
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on a more restricted overlap of binding partners between PBD1 and 2.
To address this overlap in more detail, we probed the GST–PBD pull-
downs with anti-MPM-2, an antibody known to recognize a large
number of mitotic phospho-proteins, some of which were shown to
bind to PBD1 [39]. Indeed, we ﬁnd that PBD1 can bind a variety of
these phospho-proteins, while only a few of these phospho-proteins
bind to PBD2 (Fig. 4B). Nonetheless, PBD2 does appear to recognize
mitotic phospho-proteins that might also bind to PBD1 (Fig. 4B, closed
asterisks), in addition to a phospho-protein that is not recognized by
GST–PBD1 (Fig. 4B, open asterisk). To conﬁrm that the major mitotic
phospho-protein of ~85 kDa bound to GST–PBD2 that is detected by
MPM2-staining also interacts with GST–PBD1, we ﬁrst incubated cell
lysates with GST–PBD2, followed by incubation with GST–PBD1. Prior
incubation with GST–PBD2 resulted in a speciﬁc reduction in binding
of GST–PBD1 to this ~85 kDa protein that appears to be present in theFig. 4. Interaction of phosphorylated proteins with PBDs1-4. (A) Extracts were prepared
from mitotic cells (M) by mitotic shake-off, cells remaining attached to the dish were
harvested as the interphase fraction (I). Extracts were incubatedwith the indicated GST-
fusion proteins, or GST-control coupled to agarose beads. The resulting protein
complexes were extensively washed and analyzed on Western blots with the indicated
antibodies. Total cell lysates were loaded as input control. (B) Mitotic lysates were
incubated with the indicated GST-fusions or GST-control coupled to agarose beads. The
resulting protein complexes were extensively washed and analyzed on Western blots
using anti-MPM-2. Closed asterisks indicated GST–PBD2 interactors that co-migrate
with MPM-2-recognized proteins that bind to GST–PBD1, open asterisk indicates an
MPM2-positive protein bound to GST–PBD2 that is not bound to GST–PBD1. (C) Mitotic
lysates were used in pull-downs with GST–PBD1 and 2 as under (B), but in this case a
portion of the lysatewas ﬁrst incubated with GST–PBD2 to remove all PBD2-interactors,
followed by pull-down with GST–PBD1. Asterisk indicates position of the ~85 kDa
MPM-2-reactive protein that interacts with PBD1 and 2.
Fig. 3.Mitotic progression in Plk1-depleted cells reconstituted with PBD-swapmutants.
(A) The duration of mitosis was determined as the time from nuclear envelope
breakdown until cleavage furrow ingression. The median value (marked by horizontal
line) for the time of mitotic duration in each population are shown. (B) Chromosome
alignment defects were categorized into no alignment during imaging (black bars),
alignment that took more than 45 min. starting from nuclear envelope breakdown
(delayed alignment; dark grey bars), unstable alignment with chromosomes shortly
detaching from the metaphase plate (light grey bars) or normal alignment (within
45 min; white bars).GST–PBD2 pull-down, conﬁrming that PBD1 and 2 can bind to
identical proteins, but the overlap in binding partners is limited. Taken
together, these data indicate that PBD2 can only bind a subset of PBD1-
binding proteins, consistent with our ﬁnding that it only replaces part
of the function of PBD1.
4. Discussion
Here we show that the afﬁnity of an optimal and a physiological
phospho-peptide to the PBD's differs within one or three orders of
magnitude between PBD1-3, and is practically absent for PBD4 (data
not shown). The afﬁnity for the binding of the optimal peptide to PBD1
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by Isothermal Titration Calorimetry (ITC) in the original study [11]
(280 nM). The ten times difference can be explained by the different
experimental setup and possibly a more homogenous protein
preparation resulting to tighter apparent binding in our case. The
afﬁnity we determine is however in rather sharp contrast to the much
weaker one reported by Montoya et al. [13] for the same peptide
(2770 nM) [13]. Similarly, the afﬁnity we determine for the Cdc25C
derived physiological peptide by SPR (82 nM) contradicts the values
reported in [13] (1050 nM). It must also be noted, that while in our
hands the optimal peptide reported by Yaffe is indeed optimal at least
compared to the Cdc25C derived peptide (kD of 31 nM compared to
82 nM), Montoya and co-workers observe the reverse; weaker binding
of the optimal peptide compared to the Cdc25C one (kD of 2770 nM
compared to 1050 nM).
The binding of PBD1 to phospho-peptides, is signiﬁcantly stronger
compared to that of PBD2 (hundred times weaker) and of PBD3
(more than hundred times weaker). These data are hard to explain
based on sequence and structural data. The (conservative) mutation
of Arg516 to Lys in PBD2 and PBD3 which might contribute to the
reduced binding and the loss of His489 in PBD2 could reduce afﬁnity
for the peptide, but more detailed structural data (structures of
liganded PBD2,3) are necessary. A possible explanation for the
reduced afﬁnity of PBD3 to the phospho-peptides is that due to its
pI (8.7, compared to 7.2 and 5.1 for PBD1 and PBD2 respectively) it
should have negative charges at physiological pH disfavoring
interaction with the negatively charged PO4 moiety of the pT
group. The PBDs peptide binding groove offers considerable plasticity
to allow many peptides to be recognized in the PBD-binding site,
possibly with considerable speciﬁcity albeit with lesser afﬁnity. In
this respect it is interesting to note that we ﬁnd that centrosome-
targeting of PBD2 requires the presence of the Plk1 kinase domain.
This suggests that PBD2 interacts with a Plk1-phosphorylated protein
on centrosomes.
We should note that the exact same PBDs, bind non-phosphory-
lated Cdc25C peptides with excellent afﬁnity (200–600 nM) and are
thus deﬁnitely functional. The observation that PBD2 and PBD3 bind
non-phosphorylated peptides actually stronger than they bind
phospho-peptides, is indeed very intriguing, but outside the scope
of this paper to examine in detail. More structural data are necessary
to conclude how the selectivity of PBDs actually works.
Our in vitro data with non-tagged PBDs (in case of PBD2 with a
small His-tag) are in agreement with our in vivo observations. Using
the optimal binding peptide, PBD1 is the best binder, PBD2 the
second best, PBD3 the worse of these three, and the ‘odd sister’,
PBD4 is a clear outlier with no detectable binding (data not shown).
The quick summary of our in vivo data indicate that PBD2 is the one
that rescues PBD1 function best; PBD3 and PBD4 are as bad.
Although we cannot claim that our biochemical afﬁnity data alone
explain our in vivo observations (since only one physiological target
peptide was tested along with the optimal one that does not exist in
the human proteome), the actual afﬁnity of the PBDs to peptides
appears to be a major determinant of their in vivo function. Bipolar
spindle formation could partially be reconstituted by all four Plk1
hybrids; consistent with the observation that speciﬁc localization to
centrosomes is not needed to induce bipolar spindle formation [37].
Nonetheless, the majority of the bipolar spindles that formed with
Kin1–PBD3 and Kin1–PBD4 lacked matured centrosomes, indicating
that these spindles were abnormal. Interestingly, the ability of the
various PBD-swaps to reconstitute normal bipolar spindle formation,
with mature centrosomes correlated well with the ability of the
respective swaps to promote recruitment of Aurora A to centro-
somes, with Kin1–PBD2 being the most potent swap-mutant to
reconstitute this particular function. Also, it is this latter fusion that
appears to have a number of interactors in common with Kin1–PBD1,
based on our data with GST–PBD pull-downs of MPM-2-positivephospho-proteins. These data combined clearly indicate that PBD2
can functionally reconstitute a subset of PBD1-functions and point to
a partial overlap in binding speciﬁcities between PBD1 and 2. Our
time-lapse analysis of Kin1–PBD1 and Kin1–PBD2-reconstituted cells
further corroborate these ﬁndings. Formally, we cannot rule out the
possibility that both the Kin1–PBD3 and 4 fusions do restore Plk1's
function in spindle assembly, but interfere with spindle assembly at
a different level. However, expression of the same fusions in cell
expressing normal endogenous levels of Plk1 did not result in any
obvious spindle defect, strongly suggesting that the failure to
reconstitute Plk1 function is due to the lack of functional conserva-
tion between PBD1 and PBD3 or 4.
Yaffe and co-workers have recently shown that PBD1 is a
promiscuous partner of many intra-cellular proteins, and have
identiﬁed and characterized many of them [39]. Our data show that
the binding afﬁnities of the PBDs for an optimal PBD1 peptide differ
signiﬁcantly. We also show some limited overlap in binding partners,
between PBD1 and PBD2. This warrants a proteomics approach using
similar methodologies to decipher targets that are speciﬁc for PBD2, 3
and 4 and not PBD1.
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